Technology & Innovation Platform
Biomedical technology is one of the important fields of high-tech development in the world today. The biomedical industry is another high-tech industry with broad development prospects after the information industry. It is bound to become a new growth point and pillar industry of my country's economy in this century. The continuous innovation and development of biomedical technology will definitely drive the improvement of the level of life science, clinical medicine, and environmental science and technology, and will have a huge and far-reaching impact on promoting the process of industrialization, improving the overall national strength, and human civilization and progress. The establishment of the biomedical platform aims to build a biomedical and innovation platform with highly shared resources and effective management and coordination through the integration of existing resources and equipment, and promote the efficient and sustainable development of Angdajiuli in the field of biomedicine.
24
Million yuan in research and development funding
10
Year research cycle
R&D Team
Our R&D team is composed of Nobel Prize nominees, domestic and foreign academicians, professors, top experts, as well as researchers from Zhejiang University and Huayang Pharmaceuticals.
-
Ma Huayang, Company founder, legal person
• Engineer, special researcher of the Institute of Technology Management, China Academy of Management Sciences
•Vice President of the Great Health Industry Branch of China Pharmaceutical Culture Research Association
• Currently serving as the chairman and general manager of Angda Jiuli
-
Kong Jianlong, Director of R&D Technology
•Master of Chinese Pharmacy, Shanghai University of Traditional Chinese Medicine
• Expertise in pharmacology and toxicology research, biological activity research, registration application, R&D management
• Currently serving as the director, deputy general manager and R&D director of Angda Jiuli, responsible for E2HSA R&D
-
Qin Jian, Head of Process R&D
• Bachelor of Shandong Agricultural University
• Expertise in protein process research
• Currently responsible for the research and development of the purification process of the project
-
Xu Xiaorong, Head of Genetic Engineering
•Master of Biochemistry and Molecular Biology, Zhejiang University
• Specializes in gene cloning and expression of foreign proteins (strains), gene fragment amplification, and experimental data analysis
• Currently responsible for clone screening of engineered strains, etc.
-
Zhan Jinbiao, initiator of the E2HSA project
•Professor of Zhejiang University School of Medicine, former head of the Genetic Engineering and Antibody Drug Research Group
• Director of the Biopharmaceutical Committee of Zhejiang Pharmaceutical Association
• E2HSA project sponsor and overall manager
-
Tang Huashen, Chief Scientific Advisor
•Academician of Australian Academy of Sciences, Academy of Engineering, Royal Society of Chemistry, the ninth batch of "National Thousand" plan to introduce talents
•Successfully led the research and development of "reversible addition-fragmentation chain transfer polymerization" (RAFT) method, and was nominated for the 2014 Nobel Prize in Chemistry; research and development has been widely cited in more than 13,000 academic papers, and has been applied in the field of nano-biomedicine research in recent years a major breakthrough
•Participate in the research and development cooperation with our company's new pipeline project
-
Sun Jiuru, The Company's Industrialization Expert
• Former Professor of Medicine at Monash University, Australia
• Obtained more than 40 patented inventions including recombinant expression of human lysozyme, novel fusion protein and its production method, and production method of recombinant human proinsulin C-peptide
•Provide technical guidance mainly in scale-up production. Currently, responsible for the management of the industrialization of the project
-
Maochen Xiaolin, Company Consultant
• Professor of Biology, University of Melbourne
• Has the plant Arabinogalactan protein (AGP) gene patent and is widely used, participated in writing and publishing more than 60 papers
•Provide protein recombination, fermentation and separation and purification technology in the E2HSA project, and provide technical guidance for laboratory research, industrialization and GMP certification, etc.
